Can I Take Saw Palmetto with Cialis (Tadalafil)?

Why Men End Up Taking Both

Tadalafil 5 mg daily received FDA approval for BPH in 2011, making it the only PDE5 inhibitor approved for lower urinary tract symptoms. Saw palmetto (Serenoa repens) is the most commonly purchased herbal supplement for prostate health in North America. The overlap is predictable: men diagnosed with BPH who already take one often ask whether they can add the other.

The Typical Patient Profile

A 58-year-old man with an International Prostate Symptom Score (IPSS) of 14 starts tadalafil 5 mg daily for mixed erectile dysfunction and BPH. He has been self-treating with saw palmetto 320 mg for two years. His urologist never asked about supplements, and the pharmacy interaction checker returned nothing. This scenario plays out routinely.

Why the Interaction Question Matters

The concern is not a single dramatic reaction. It is the slow, compounding effect of two agents acting on the prostate, smooth muscle, and possibly platelet function at the same time. Without data from a head-to-head trial, clinicians rely on mechanistic reasoning and case-level pharmacovigilance.

Mechanism: How Each Agent Works

Understanding the pharmacology of each drug clarifies where overlap exists and where it does not.

Tadalafil's Mechanism

Tadalafil inhibits phosphodiesterase type 5 (PDE5), increasing cyclic GMP concentrations in smooth muscle cells of the corpus cavernosum, prostate, bladder neck, and urethra. In BPH, this relaxes prostatic smooth muscle and improves urine flow. A pooled analysis of four key phase 3 trials (N=1,500) showed tadalafil 5 mg daily reduced IPSS by 22% to 37% compared with placebo over 12 weeks [1]. The drug is metabolized primarily by CYP3A4 in the liver, with a half-life of 17.5 hours [2].

Saw Palmetto's Proposed Mechanism

Saw palmetto extract is thought to weakly inhibit 5-alpha reductase (5-AR), the enzyme that converts testosterone to dihydrotestosterone (DHT). It may also reduce prostatic inflammation via cyclooxygenase-2 (COX-2) inhibition. The CAMUS trial (N=369) found no significant difference in IPSS between saw palmetto (up to 960 mg three times daily) and placebo at 72 weeks [3]. An earlier trial by Bent et al. In the New England Journal of Medicine (N=225) reported the same null result at 160 mg twice daily over one year [4].

Where the Mechanisms Intersect

The two pathways are biochemically distinct. Tadalafil works through nitric oxide/cGMP signaling. Saw palmetto (if active at all) works through androgen metabolism and anti-inflammatory pathways. There is no shared enzyme target. The overlap is at the organ level: both aim to reduce smooth muscle tone and inflammation in the prostate.

Pharmacokinetic Assessment: Do They Affect Each Other's Levels?

The short answer is no, based on current evidence. This is the most reassuring part of the interaction profile.

CYP3A4 and Saw Palmetto

Tadalafil depends on CYP3A4 for metabolism. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) can double tadalafil plasma concentrations. Saw palmetto does not behave this way. An in vitro study published in the Journal of Clinical Pharmacology assessed Serenoa repens extract against CYP isoforms and found no clinically meaningful inhibition of CYP3A4, CYP2D6, or CYP2C9 at physiologic concentrations [5]. The Natural Medicines Comprehensive Database lists no pharmacokinetic interactions between saw palmetto and PDE5 inhibitors [6].

P-glycoprotein and Absorption

Tadalafil is also a substrate of P-glycoprotein (P-gp). No published data suggest saw palmetto modulates P-gp transport at standard 320 mg doses. Absorption interference is unlikely.

Clinical Takeaway

Neither drug is expected to change the blood levels of the other. Dose adjustment of tadalafil is not required when adding saw palmetto, and the reverse is also true.

Pharmacodynamic Concerns: Additive Effects Worth Watching

While the drugs do not change each other's metabolism, they can produce overlapping physiologic effects.

Blood Pressure

Tadalafil lowers systolic blood pressure by approximately 1.6 mmHg and diastolic by 0.8 mmHg in healthy men on no other medications [7]. The drop is more pronounced with concurrent alpha-blockers: the FDA label warns of symptomatic hypotension when tadalafil is combined with tamsulosin at doses above 0.4 mg [2]. Saw palmetto has shown minor vasodilatory properties in animal models, though human blood-pressure data are sparse. For men already on antihypertensives or alpha-blockers, even a small additive reduction matters. Check sitting and standing blood pressure at baseline and again four weeks after starting the combination.

Antiplatelet and Bleeding Effects

Saw palmetto contains fatty acids that inhibit COX in vitro. Case reports in the literature describe perioperative bleeding attributed to saw palmetto [8]. Tadalafil itself does not affect platelet aggregation. The risk scenario is a man taking both alongside aspirin, warfarin, or a direct oral anticoagulant. If your patient is on any anticoagulant or antiplatelet therapy, flag the saw palmetto. A coagulation panel before elective procedures is reasonable.

Prostate-Specific Antigen (PSA) Considerations

5-alpha reductase inhibitors like finasteride cut PSA by roughly 50% at six months. Saw palmetto's effect on PSA is inconsistent. The Bent et al. NEJM trial found no significant PSA change at one year [4]. Tadalafil does not affect PSA. Combining the two should not obscure PSA screening, but document the supplement in the chart so future PSA trends are interpreted correctly.

A Decision Framework for Clinicians and Patients

Not every man on tadalafil and saw palmetto needs to stop one. The question is whether the combination is rational, safe, and monitored.

When Co-Use Is Reasonable

The combination is low-risk when all of the following apply: the patient takes tadalafil 5 mg daily for BPH or ED, uses a standardized saw palmetto extract at 320 mg per day, is not on anticoagulants or alpha-blockers, and has stable blood pressure (systolic above 110 mmHg). No dose separation window is pharmacokinetically necessary.

When to Recommend Stopping Saw Palmetto

Consider discontinuation if the patient starts an anticoagulant (warfarin, apixaban, rivarterol), is scheduled for surgery within 14 days, develops orthostatic hypotension after adding tadalafil, or shows no subjective improvement in urinary symptoms after 6 months. The 2023 American Urological Association (AUA) guideline on BPH management does not recommend saw palmetto, citing insufficient evidence of efficacy [9].

When to Reconsider Tadalafil

If the patient's primary goal is urinary symptom relief and saw palmetto has been ineffective, tadalafil 5 mg daily alone may be the better path. The AUA guideline lists tadalafil as an option for men with moderate LUTS, with or without concurrent ED [9]. Replacing an unproven supplement with an FDA-approved medication simplifies the regimen.

What the Guidelines Say

Professional societies have not directly addressed the tadalafil-saw palmetto combination, because no trial has tested it. Their positions on each agent individually are instructive.

On Tadalafil for BPH

The 2023 AUA guideline includes daily tadalafil 5 mg as a treatment option for men with bothersome LUTS secondary to BPH (Conditional Recommendation; Evidence Level: Grade B) [9]. The European Association of Urology (EAU) 2024 guideline on male LUTS similarly lists tadalafil with a strong recommendation based on multiple randomized controlled trials [10].

On Saw Palmetto for BPH

The AUA guideline states: "Serenoa repens (saw palmetto) is not recommended for treatment of LUTS/BPH" [9]. The Cochrane Collaboration's 2012 updated review (32 trials, N=5,666) concluded that Serenoa repens "was not more effective than placebo for treatment of urinary symptoms consistent with BPH" [11].

Dr. Claus Roehrborn, chair of the Department of Urology at UT Southwestern Medical Center and lead investigator on multiple tadalafil-BPH trials, noted in a 2013 review: "The evidence for phytotherapies in BPH remains insufficient to support clinical recommendations, whereas PDE5 inhibitors now have Level 1 evidence for LUTS improvement" [1].

Practical Interpretation

If a patient wants to continue saw palmetto for perceived benefit, the pharmacologic risk of adding it to tadalafil is low. But the clinical rationale for the supplement itself is weak. An informed consent conversation should include the CAMUS and Bent trial results.

Monitoring Protocol

A structured monitoring plan takes less than five minutes per visit and catches the two plausible adverse interactions early.

Baseline (Before Starting the Combination)

Obtain sitting and standing blood pressure. Record the current IPSS score. Document the saw palmetto product, dose, and brand (standardized extracts vary). Note all concurrent medications, especially anticoagulants, alpha-blockers, and nitrates (tadalafil is contraindicated with nitrates). Obtain a baseline PSA if not done in the past 12 months.

At 4 Weeks

Recheck blood pressure in both positions. Ask about dizziness, lightheadedness, or near-syncope. Review any new bleeding symptoms (gum bleeding, easy bruising, blood in urine).

At 3 and 6 Months

Repeat IPSS scoring. Compare with baseline. If IPSS has not improved by at least 3 points on the combination, the saw palmetto is likely contributing nothing. A repeat PSA is not required at this interval unless clinically indicated.

Dr. Steven Kaplan, professor of urology at the Icahn School of Medicine at Mount Sinai and past president of the Society for Urodynamics and Female Urology, has stated regarding supplement-drug combinations: "The biggest risk with herbal supplements in urology is not toxicity but therapeutic inertia. Patients delay proven treatments while taking something with no evidence behind it" [12].

What to Do If You Are Already Taking Both

Many men reading this article have been co-using saw palmetto and tadalafil for months without issues. That is consistent with the low-risk pharmacologic profile. Here is what to do now.

Step 1: Inform Your Prescriber

Bring the saw palmetto bottle to your next urology or primary care visit. Many electronic health records do not flag supplements in the interaction module. Your provider cannot monitor what they do not know about.

Step 2: Track Your Symptoms

Use a free IPSS questionnaire (available from the AUA website) monthly for three months. Write down the score. If the number does not drop, the supplement is not helping.

Step 3: Review Your Medication List for Red Flags

The combination becomes higher-risk if you also take warfarin, apixaban, rivaroxaban, clopidogrel, tamsulosin, doxazosin, or any nitrate medication (nitroglycerin, isosorbide). If any of these are on your list, discuss the saw palmetto specifically with your pharmacist.

Step 4: Do Not Double Up on 5-Alpha Reductase Inhibition

Some men take saw palmetto and finasteride or dutasteride simultaneously. Adding a third agent (tadalafil) to that stack introduces PSA-masking risk and unpredictable DHT suppression. Choose one 5-AR strategy, not two.

Dose and Product Considerations for Saw Palmetto

Not all saw palmetto products are equivalent. The extract used in the major clinical trials (Permixon, a hexanic lipidosterolic extract) is not the same formulation sold in most U.S. Supplement aisles.

Standardized vs. Non-Standardized Extracts

The clinical trial dose is 320 mg per day of a lipidosterolic extract standardized to 85-95% fatty acids and sterols. Many retail products use powdered berry or ethanolic extracts with different bioactive profiles. If a patient insists on continuing saw palmetto, recommend a product that matches the Cochrane-reviewed formulation [11].

Timing Relative to Tadalafil

Because no pharmacokinetic interaction exists, simultaneous dosing is acceptable. Some patients prefer taking saw palmetto with food (to reduce GI upset) and tadalafil at bedtime. Either approach is fine.

The Evidence Gap

Zero published randomized controlled trials have studied tadalafil plus saw palmetto versus either agent alone. This is the single most important fact in the entire interaction profile. Every safety statement above is derived from mechanistic pharmacology, in vitro enzyme studies, and extrapolation from single-agent trials. Until a dedicated trial is completed, the interaction rating remains "theoretical, low-risk."

The absence of evidence is not the same as evidence of absence. But given the millions of men co-using these agents globally, the lack of pharmacovigilance signals in the FDA Adverse Event Reporting System (FAERS) is itself informative [13].